DOXIMITY INC-CLASS A (DOCS) Stock Fundamental Analysis

NYSE:DOCS • US26622P1075

25.22 USD
-0.74 (-2.85%)
Last: Feb 12, 2026, 09:52 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

8

Overall DOCS gets a fundamental rating of 8 out of 10. We evaluated DOCS against 35 industry peers in the Health Care Technology industry. DOCS has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. DOCS is growing strongly while it is still valued neutral. This is a good combination! With these ratings, DOCS could be worth investigating further for growth and quality investing!.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • In the past year DOCS was profitable.
  • DOCS had a positive operating cash flow in the past year.
  • Each year in the past 5 years DOCS has been profitable.
  • In the past 5 years DOCS always reported a positive cash flow from operatings.
DOCS Yearly Net Income VS EBIT VS OCF VS FCFDOCS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

1.2 Ratios

  • DOCS has a better Return On Assets (20.69%) than 100.00% of its industry peers.
  • DOCS has a Return On Equity of 24.45%. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
  • DOCS has a better Return On Invested Capital (19.48%) than 100.00% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for DOCS is significantly above the industry average of 6.72%.
  • The 3 year average ROIC (14.17%) for DOCS is below the current ROIC(19.48%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 20.69%
ROE 24.45%
ROIC 19.48%
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
DOCS Yearly ROA, ROE, ROICDOCS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 5 10 15 20 25

1.3 Margins

  • With an excellent Profit Margin value of 37.54%, DOCS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • DOCS's Profit Margin has improved in the last couple of years.
  • DOCS has a better Operating Margin (37.44%) than 100.00% of its industry peers.
  • In the last couple of years the Operating Margin of DOCS has grown nicely.
  • With an excellent Gross Margin value of 89.75%, DOCS belongs to the best of the industry, outperforming 97.14% of the companies in the same industry.
  • DOCS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 37.44%
PM (TTM) 37.54%
GM 89.75%
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
DOCS Yearly Profit, Operating, Gross MarginsDOCS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), DOCS is creating value.
  • Compared to 1 year ago, DOCS has more shares outstanding
  • DOCS has more shares outstanding than it did 5 years ago.
  • DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DOCS Yearly Shares OutstandingDOCS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
DOCS Yearly Total Debt VS Total AssetsDOCS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 18.32 indicates that DOCS is not in any danger for bankruptcy at the moment.
  • DOCS has a better Altman-Z score (18.32) than 94.29% of its industry peers.
  • DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 18.32
ROIC/WACC2.04
WACC9.54%
DOCS Yearly LT Debt VS Equity VS FCFDOCS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.3 Liquidity

  • DOCS has a Current Ratio of 6.63. This indicates that DOCS is financially healthy and has no problem in meeting its short term obligations.
  • DOCS has a Current ratio of 6.63. This is amongst the best in the industry. DOCS outperforms 88.57% of its industry peers.
  • DOCS has a Quick Ratio of 6.63. This indicates that DOCS is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 6.63, DOCS belongs to the best of the industry, outperforming 88.57% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.63
Quick Ratio 6.63
DOCS Yearly Current Assets VS Current LiabilitesDOCS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 28.91% over the past year.
  • Measured over the past years, DOCS shows a very strong growth in Earnings Per Share. The EPS has been growing by 79.21% on average per year.
  • The Revenue has grown by 15.92% in the past year. This is quite good.
  • DOCS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.42% yearly.
EPS 1Y (TTM)28.91%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%2.22%
Revenue 1Y (TTM)15.92%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%9.76%

3.2 Future

  • DOCS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.76% yearly.
  • DOCS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.82% yearly.
EPS Next Y14.1%
EPS Next 2Y11.43%
EPS Next 3Y11.59%
EPS Next 5Y11.76%
Revenue Next Year14.06%
Revenue Next 2Y12.65%
Revenue Next 3Y12.04%
Revenue Next 5Y11.82%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
DOCS Yearly Revenue VS EstimatesDOCS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
DOCS Yearly EPS VS EstimatesDOCS Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 15.28, which indicates a correct valuation of DOCS.
  • DOCS's Price/Earnings ratio is rather cheap when compared to the industry. DOCS is cheaper than 82.86% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 28.18, DOCS is valued a bit cheaper.
  • A Price/Forward Earnings ratio of 14.41 indicates a correct valuation of DOCS.
  • DOCS's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. DOCS is cheaper than 77.14% of the companies in the same industry.
  • DOCS's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 28.01.
Industry RankSector Rank
PE 15.28
Fwd PE 14.41
DOCS Price Earnings VS Forward Price EarningsDOCS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, DOCS is valued a bit cheaper than 71.43% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of DOCS indicates a somewhat cheap valuation: DOCS is cheaper than 77.14% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 15.16
EV/EBITDA 13.46
DOCS Per share dataDOCS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4 5

4.3 Compensation for Growth

  • DOCS's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of DOCS may justify a higher PE ratio.
PEG (NY)1.08
PEG (5Y)0.19
EPS Next 2Y11.43%
EPS Next 3Y11.59%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • DOCS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DOXIMITY INC-CLASS A

NYSE:DOCS (2/12/2026, 9:52:10 AM)

25.22

-0.74 (-2.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)02-05
Earnings (Next)05-13
Inst Owners91.38%
Inst Owner Change0.27%
Ins Owners1.96%
Ins Owner Change0.19%
Market Cap4.66B
Revenue(TTM)637.78M
Net Income(TTM)239.40M
Analysts80
Price Target64.16 (154.4%)
Short Float %6.28%
Short Ratio3.09
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.81%
Min EPS beat(2)1.21%
Max EPS beat(2)16.41%
EPS beat(4)4
Avg EPS beat(4)17.96%
Min EPS beat(4)1.21%
Max EPS beat(4)36.67%
EPS beat(8)8
Avg EPS beat(8)20.77%
EPS beat(12)12
Avg EPS beat(12)20.67%
EPS beat(16)16
Avg EPS beat(16)21.74%
Revenue beat(2)1
Avg Revenue beat(2)2.2%
Min Revenue beat(2)-0.43%
Max Revenue beat(2)4.82%
Revenue beat(4)3
Avg Revenue beat(4)2.07%
Min Revenue beat(4)-0.43%
Max Revenue beat(4)4.82%
Revenue beat(8)6
Avg Revenue beat(8)3.12%
Revenue beat(12)8
Avg Revenue beat(12)2.38%
Revenue beat(16)11
Avg Revenue beat(16)1.96%
PT rev (1m)-7.9%
PT rev (3m)-12.09%
EPS NQ rev (1m)-0.47%
EPS NQ rev (3m)-1.03%
EPS NY rev (1m)-0.1%
EPS NY rev (3m)3.76%
Revenue NQ rev (1m)-0.03%
Revenue NQ rev (3m)0.84%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)1.64%
Valuation
Industry RankSector Rank
PE 15.28
Fwd PE 14.41
P/S 7.3
P/FCF 15.16
P/OCF 14.77
P/B 4.76
P/tB 5.44
EV/EBITDA 13.46
EPS(TTM)1.65
EY6.54%
EPS(NY)1.75
Fwd EY6.94%
FCF(TTM)1.66
FCFY6.59%
OCF(TTM)1.71
OCFY6.77%
SpS3.45
BVpS5.3
TBVpS4.64
PEG (NY)1.08
PEG (5Y)0.19
Graham Number14.03
Profitability
Industry RankSector Rank
ROA 20.69%
ROE 24.45%
ROCE 23.71%
ROIC 19.48%
ROICexc 72.13%
ROICexgc 130.98%
OM 37.44%
PM (TTM) 37.54%
GM 89.75%
FCFM 48.17%
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
ROICexc(3y)82.49%
ROICexc(5y)193.92%
ROICexgc(3y)186.25%
ROICexgc(5y)N/A
ROCE(3y)17.25%
ROCE(5y)20.05%
ROICexgc growth 3Y3.35%
ROICexgc growth 5YN/A
ROICexc growth 3Y-4.75%
ROICexc growth 5YN/A
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
F-Score7
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 62.82%
Cap/Sales 1.29%
Interest Coverage 250
Cash Conversion 125.24%
Profit Quality 128.33%
Current Ratio 6.63
Quick Ratio 6.63
Altman-Z 18.32
F-Score7
WACC9.54%
ROIC/WACC2.04
Cap/Depr(3y)59.31%
Cap/Depr(5y)83.25%
Cap/Sales(3y)1.28%
Cap/Sales(5y)1.55%
Profit Quality(3y)131.35%
Profit Quality(5y)169.54%
High Growth Momentum
Growth
EPS 1Y (TTM)28.91%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%2.22%
EPS Next Y14.1%
EPS Next 2Y11.43%
EPS Next 3Y11.59%
EPS Next 5Y11.76%
Revenue 1Y (TTM)15.92%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%9.76%
Revenue Next Year14.06%
Revenue Next 2Y12.65%
Revenue Next 3Y12.04%
Revenue Next 5Y11.82%
EBIT growth 1Y6.94%
EBIT growth 3Y26.56%
EBIT growth 5Y59.63%
EBIT Next Year17.75%
EBIT Next 3Y13.76%
EBIT Next 5Y12.86%
FCF growth 1Y90.12%
FCF growth 3Y30.18%
FCF growth 5Y64.72%
OCF growth 1Y89.16%
OCF growth 3Y29.24%
OCF growth 5Y59.83%

DOXIMITY INC-CLASS A / DOCS FAQ

What is the fundamental rating for DOCS stock?

ChartMill assigns a fundamental rating of 8 / 10 to DOCS.


What is the valuation status for DOCS stock?

ChartMill assigns a valuation rating of 6 / 10 to DOXIMITY INC-CLASS A (DOCS). This can be considered as Fairly Valued.


How profitable is DOXIMITY INC-CLASS A (DOCS) stock?

DOXIMITY INC-CLASS A (DOCS) has a profitability rating of 9 / 10.


What are the PE and PB ratios of DOXIMITY INC-CLASS A (DOCS) stock?

The Price/Earnings (PE) ratio for DOXIMITY INC-CLASS A (DOCS) is 15.28 and the Price/Book (PB) ratio is 4.76.


What is the earnings growth outlook for DOXIMITY INC-CLASS A?

The Earnings per Share (EPS) of DOXIMITY INC-CLASS A (DOCS) is expected to grow by 14.1% in the next year.